ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations under the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers that impacted patient access to its drugs XPHOZAH and IBSRELA, causing delays in new-patient starts and prescription fulfillment. The class period runs from January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.